Clinical trials
Clinical High Risk clinical trials
Below are recruiting clinical high risk clinical trials, each written for real people, not researchers. We’re tracking 566 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Birmingham, AlabamaAges 18 years+ - NCT06851806Recruiting
Palivizumab study for children at high risk of severe RSV
This study tests a medication called palivizumab to help protect certain children from severe RSV (a common respiratory virus). It is for infants and young children with a higher chance of getting very sick from RSV, such as premature babies or those with certain heart or lung conditions.
HyderabadAges Any age - NCT06887621RecruitingPhase 2
Adding oral amisulpride to prevent nausea after gynecologic surgery
This trial tests if adding a medication called amisulpride to standard anti-nausea drugs can better prevent vomiting and nausea after gynecologic surgery. It is for women at high risk of postoperative nausea.
São Paulo, São PauloAges 18 years+ - NCT06524583RecruitingPhase 2
Chemotherapy after surgery for high-risk uterine leiomyosarcoma
This trial tests whether chemotherapy after surgery can help prevent uterine leiomyosarcoma from coming back in patients who are at high risk based on a genetic test of their tumor. It is for women with early-stage cancer (stage I) who have had complete surgery.
AngersAges 18–75 - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+ - NCT06247501RecruitingPhase 2
CAR-T therapy for children with B-cell ALL needing transplant
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
SeoulAges Up to 25 years - NCT05834764RecruitingPhase 2
Pyrotinib for high-risk HER2-positive early breast cancer
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Nanjing, JiangsuAges 18–75 - NCT05272371RecruitingPhase 1
Dinutuximab beta plus chemo for childhood neuroblastoma after relapse
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Krakow, MalopolskaAges 1–18 - NCT05392764RecruitingPhase 3
SGLT2 medicine for high-risk people after sudden worsening heart failure
This Phase 3 trial tests whether starting an SGLT2 inhibitor early in the hospital can improve outcomes for people at high risk after acute (sudden) heart failure. If you qualify, you would be randomized to receive the study medicine or standard care, started within 12 hours of admission.
Anjo, Aichi-kenAges 20 years+ - NCT05238792RecruitingPhase 1
Immune cells to treat high-risk solid tumors in children
This trial tests a type of immunotherapy using special white blood cells (T-cells) that are trained to find and attack cancer cells. It is for children and young adults with high-risk solid tumors that have not gone away or have come back after standard treatment.
Washington D.C., District of ColumbiaAges 1–70 - NCT04276870RecruitingPhase 2
CD19 gene-modified cells for high-risk B-cell leukemia
This Phase 2 trial studies CD19 “redirected” cells made from your own blood to treat certain high-risk or relapsed B-cell acute lymphoblastic leukemia (B-ALL). It may help by targeting cancer cells that carry a protein called CD19.
Philadelphia, PennsylvaniaAges birth–29 years - NCT03583710RecruitingPhase 3
Mitotane after adrenal tumor surgery, with or without chemo
This study looks at whether giving mitotane after surgery (and possibly adding cisplatin/etoposide chemotherapy) helps prevent adrenal cancer from coming back. It is for people with stage I–III adrenal cortical cancer who have a high risk of relapse after their tumor was removed.
Ann Arbor, MichiganAges 18 years+ - NCT04428671RecruitingPhase 1
Cemiplimab before and after surgery for high-risk skin cancer
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
Atlanta, GeorgiaAges 18 years+ - NCT04266574Recruiting
Blood pressure–guided care for older or frail surgical patients
This study tests a goal-based blood pressure treatment approach during major surgery for people at higher risk (often older or frail with high blood pressure). The goal is to see if this BRAIN-targeted strategy can improve how patients do after surgery.
Rozzano, MilanAges 18 years+ - NCT06812039RecruitingPhase 2
Perioperative treatment for high-risk liver cancer using HAIC, donafenib, and sintilimab
This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.
Fuzhou, FujianAges 18–75 - NCT06798558RecruitingPhase 2
Lu-PSMA before prostate surgery for high-risk cancer
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Atlanta, GeorgiaAges 1–30 - NCT05852223RecruitingPhase 2
Pembrolizumab for high-risk thyroid cancer that cannot be fully removed
This study tests pembrolizumab (an immune therapy) in people with high-risk thyroid cancer that is hard to treat with surgery alone. It looks at whether this drug can reduce persistent or recurrent cancer after your planned treatment.
Pavia, LombardyAges 18 years+ - NCT06156943Recruiting
Fluid monitoring during lung surgery for high-risk patients
This study tests a new way to monitor your body's fluid levels during lung surgery, especially for patients who are at higher risk for complications. The goal is to improve recovery and reduce problems after surgery.
BronAges 18–80 - NCT06348264RecruitingPhase 2
Rezvilutamide with hormone therapy for high-risk salivary duct cancer
This trial tests a new drug, Rezvilutamide, combined with standard hormone therapy for people with a rare and aggressive type of salivary gland cancer that has a high risk of coming back. The treatment aims to reduce the chance of cancer returning after surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06120387Recruiting
Radiation after kidney-sparing surgery for high-risk ureteral cancer
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
BeijingAges 18 years+ - NCT06833827Recruiting
Clot removal vs clot-busting drugs for severe lung clots
This study compares two ways to treat a large blood clot in the lungs that is causing life-threatening symptoms. One method uses a device to remove the clot, the other uses medicine to dissolve it.
Leiden, South HollandAges 18 years+ - NCT06221670RecruitingPhase 2
Toripalimab after surgery for high-risk early lung cancer
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06499870RecruitingPhase 2
Study of two drugs with radiation for high-risk prostate cancer
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
Chicago, IllinoisAges 18 years+
Hear when a new Clinical High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical high risk?
- Yes. Clin2 currently lists 566 recruiting clinical high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.